Endocyte slashes staff and retrenches in the wake of back-to-back R&D setbacks
Three years after Endocyte’s shares $ECYT were shredded by the failure of its lead cancer program and Merck’s decision to exit their partnership, the little …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
